reports
ICON Reports First Quarter 2024 Results
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2024. CEO, Dr. Steve Cutler commented, “ICON reported a strong start to the year in quarter one, with revenue growth of 6% year over year, and net bookings up 10% over quarter one 2023, resulting in a net book to bill ratio of 1.27 times. Adjusted earnings per share grew a robust 20% on a year over year basis, reflecting our efficient service delivery and strong cost control. Our performance is reflec...
ICON Announces CFO Transition
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry. Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer. ICON has commenced a search to identify the next CFO. “On behalf of the ICON Board and Leadership Team, I want to thank Brendan for his st...
ICON plc Schedules First Quarter 2024 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, April 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 25, 2024 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. A webcast replay of the conference call will be availab...
ICON plc to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 2:05 pm ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. About ICON plc...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WING WINGSTOP INC.
PBPB POTBELLY CORP.
IRM IRON MOUNTAIN INC.
ICLR ICON PLC
FAN FABRINET
FCN FTI CONSULTING INC.
CAMT CAMTEK LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
KLAC KLA CORPORATION
SPOK SPOK HOLDINGS
ELF E.L.F. BEAUTY INC.
CRSP CRISPR THERAPEUTICS AG
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
AVGO BROADCOM INC.
AMEH APOLLO MEDICAL HOLDINGS INC
DELL DELL TECHNOLOGIES INC CLASS C
TNL TRAVEL PLUS LEISURE CO
MRVL MARVELL TECHNOLOGY INC
RELY REMITLY GLOBAL INC
JANX JANUX THERAPEUTICS INC
BTMD ONTO INNOVATION INC.
ROOT HAYMAKER ACQUISITION CORP III
COHR ROOT INC
CDRO COHERENT CORP
SKWD CODERE ONLINE LUXEMBOURG SA
WGS SKYWARD SPECIALTY INS GROUP INC
GENEDX HOLDINGS CORP.
ICON Reports Fourth Quarter and Full Year 2023 Results
DUBLIN--(BUSINESS WIRE)-- (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and year ended December 31, 2023. CEO, Dr. Steve Cutler commented, “With our focus on delivering innovative clinical development solutions, ICON’s solid performance in quarter four and the full year 2023 reflects continued market leadership across the customer segments we serve. Our team delivered strong financial results despite challenging macroeconomic conditions, resulting in full year adjusted EBITDA growth of 1...
ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Confere...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 22, 2024 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. A webcast replay of the co...
New ICON Survey Highlights Importance of Combination Therapies in Futu...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area. The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome. There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with ...
ICON Issues Financial Guidance for Full Year 2024
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2024. For the full year 2024, revenue is expected to be in the range of $8,400 - $8,800 million, representing growth of 3.2% – 8.1%, and adjusted earnings per share1 is expected to be in the range of $14.50 - $15.30, representing growth of 13.5% – 19.8%, over Full Year 2023 revenue and adjusted earnings per share guidance midpoints, respectively. CEO Dr. Steve Cutler commented, “ICON’s position a...
Biotech companies to increase R&D spend but highlight complexity of cl...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding. A executives, published by ICON, shows that 60% of respondents expected to increase R&D spending, whilst only 2% planned to reduce funding. While respondents were confident in their outlook with regards to investment milestones ...
ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conferen...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15pm PST/8.15pm EST. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research...
ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial ...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation. In recognition of its Environmental, Social and Governance (ESG) efforts and as an employer of choice, ICON ranked 88th in TIME’s list of the World’s Best Companies of 2023, the highest ranking CRO within the top 750 companies included. The award evaluates companies using standardised KPIs on sustainability, revenue and employee satisfaction. ICON...
ICON Secures Upgraded Credit Rating from Moody’s Investors Service
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument ratings to Baa3 with a stable outlook. This reflects the stronger credit profile of the ICON Group, which Moody’s now views as comparable in aggregate to Baa3 peers. The Baa3 rating of all the instruments reflects Moody’s view that the ICON Group has reached an investment grade financial profile. Moody’s highlighted in their report that the upgrade of the debt instruments reflect...
ICON plc to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 2:00pm GMT. Mr. Brendan Brennan will also present at the Evercore HealthCONx Conference on Wednesday, November 29, 2023, at 12:30pm ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. About ICON plc ICON plc is a world-leadi...
ICON Reports Third Quarter 2023 Results
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2023. CEO, Dr. Steve Cutler commented, “ICON delivered impressive results in the third quarter, with revenue growth of 6% year over year, as well as double digit adjusted EBITDA and adjusted earnings per share growth of 14% and 10%, respectively, over quarter three 2022. Our net book to bill improved to 1.26x in the quarter, reflective of the healthy demand for our market-leading offering across t...
ICON Secures Upgraded Credit Rating from S&P Global Ratings
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging. S&P upgraded ICON from a ‘BB+’ rating to a ‘BBB-’, raising their long-term issuer credit rating and their issue rating on the group’s senior secured term debt. S&P highlighted in their report, “ICON’s solid operating performance and voluntary debt prepayments improve credit metrics to a level commen...
ICON plc Schedules Third Quarter 2023 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2023 after the market closes on Wednesday, October 25, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 26, 2023 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. A webcast replay of the conference call will be ava...
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly i...
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines ...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates. Next generation COVID-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.